Clinical trials: Patients with Advanced Solid Tumors
Neoplasms
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory…
- Trial name
- NCT01881217
- Testing
- BAY1179470
- Where
- 8 sites in Japan, Singapore and 1 more
- Volunteers
- 35 people
- Sponsor
- Bayer
Solid Tumor, Adult
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
BY101921 is a novel small molecule, being developed as a PARP7 inhibitor which acts on the PARP7 catalytic subunit, for the treatment of solid tumors.
- Trial name
- NCT06433726
- Testing
- BY101921 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Tumors
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose)…
- Trial name
- HMPL-504 (NCT01985555)
- Testing
- Volitinib(HMPL-504)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Advanced Solid Tumor
APL-102 Capsule in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.
- Trial name
- NCT05055518
- Testing
- APL-102 Capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Apollomics Inc.
Advanced Solid Tumors
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
This is a randomized, open-label, two-period, crossover trial to evaluate the pharmacokinetic profiles of albumin-bound docetaxel for intravenous infusion and Taxotere in patients with advanced solid tumors.
- Trial name
- NCT04811118
- Testing
- Docetaxel for Injection (Albumin-bound), Taxotere
- Where
- China
- Volunteers
- 27 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Solid Tumor
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting.
- Trial name
- NCT02590952
- Testing
- Epitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Hutchison Medipharma Limited
Solid Tumor, Adult
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
This is an open label Phase 1a/1b study in patients who have advanced solid cancer tumours. Patients will receive MTL-CEBPA (an experimental drug) in combination with pembrolizumab (a drug which has been given approval for use…
- Trial name
- TIMEPOINT (NCT04105335)
- Testing
- MTL-CEBPA, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Mina Alpha Limited
Malignant Solid Tumors
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
- Trial name
- NCT05508620
- Testing
- Sirolimus for Injection (Albumin-bound)
- Volunteers
- 270 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumors
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or…
- Trial name
- NCT03539484
- Testing
- RO7172508, Obinutuzumab, Tocilizumab
- Where
- 6 sites in Belgium, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Refractory Solid Tumors
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132.
- Conditions
- Lymphoma, Refractory Solid Tumors, Advanced Cancer
- Trial name
- NCT02383368
- Testing
- ASP4132
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Tumors
INNO-105 in Patients With Solid Tumors
The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer drug, are being studied in patients with solid tumors.
- Trial name
- NCT00255333
- Testing
- INNO-105
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Innovive Pharmaceuticals
Advanced KRAS G12D Mutant Solid Tumors
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.
- Trial name
- NCT06385678
- Testing
- HRS-4642, Adebrelimab, SHR-9839
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.
- Trial name
- NCT07446816
- Testing
- Hemay181
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Cancer, Solid Tumors
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00973076
- Testing
- AZD8055
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Solid Tumors
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
This study is being done to evaluate the safety and pharmacokinetic profile of MK-8242 and its active metabolite (M16) in participants with advanced solid tumors.
- Trial name
- NCT01463696
- Testing
- MK-8242
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer
ITR-251 in Patients With Advanced Solid Tumors
This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway…
- Trial name
- STRIVE-251 (NCT07870096)
- Testing
- ITR-251, ITR-251 at RP2D, ARPI therapy
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- ITERIA BIOPHARMA, S.L.
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Melanoma (Skin), Non Small Cell Lung Cancer
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human…
- Conditions
- Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT06956690
- Testing
- ENV-501
- Where
- 7 sites in United States, Australia
- Volunteers
- 180 people
- Sponsor
- Hummingbird Bioscience